SOPHiA GENETICS SA (NASDAQ: SOPH) reported Q4 EPS of ($0.23), $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $17.84 million.

GUIDANCE:

SOPHiA GENETICS SA sees FY2025 revenue of $72-76 million, versus the consensus of $74.512 million. Adjusted EBITDA loss between $35 million and $39 million, compared to $40.2 million in FY 2024

For earnings history and earnings-related data on SOPHiA GENETICS SA (SOPH) click here.